Wenbin Ma , Libin Wang , Yangyang Pan , Meng Wang , Jinglei Wang , Min Feng , Junqian Wang , Hui Zhang , Rui Zhang , Zhengxing Jiao , Yan Cui , Sijiu Yu
{"title":"Beclin1 regulates yak endometrial inflammation and TLR4/NF-κB signaling pathway through autophagy/non-autophagy function","authors":"Wenbin Ma , Libin Wang , Yangyang Pan , Meng Wang , Jinglei Wang , Min Feng , Junqian Wang , Hui Zhang , Rui Zhang , Zhengxing Jiao , Yan Cui , Sijiu Yu","doi":"10.1016/j.intimp.2024.113940","DOIUrl":null,"url":null,"abstract":"<div><div>Beclin1 is an autophagy related factor, and it is capable of mediating non-autophagy functions, too. Yak endometritis represents a significant obstetric ailment that impedes the normal breeding process. The current understanding of the beclin1 effect on endometrial inflammation in yak remains limited. Accordingly, this study initially examined the expression profile of beclin1 in yak endometritis in vitro and vivo. Subsequently, the <em>beclin1</em> was targeted inhibit through small interfering RNA (siRNA), with the objective of elucidating the regulatory function of beclin1 in yak endometritis. The findings reveal that expression of beclin1 in inflammatory tissues of yak endometrium is markedly elevate in comparison to control group, and predominant localization in the cytoplasm of the endometrium and uterine glands. 1 µg/mL Lipopolysaccharide (LPS) was demonstrated to induce yak endometrial epithelial cells (YEECs) inflammation and increase the expression of beclin1. YEECs are disposed with 1 μg/mL LPS, resulting in a gradual increase of p62 expression from 0 h to 6 h, and significant decrease at 12 h, at 9 h to 12 h the expression of LC3 significant increase. These findings indicate that LPS impairs autophagy during the initial stages of inflammation, complete autophagy is occurred in cells during the subsequent phase. Initial stages of inflammation, inhibit <em>beclin1</em> result significantly reduced expression of inflammatory factors (TNF-α and IL-1β) and TLR4/NF-κB signaling pathway (p65, IκBα phosphorylation, p65 nuclear translocation) compared to the control group. When complete autophagy occurred, inhibit <em>beclin1</em> inhibit autophagy, result in a significantly higher expression of inflammatory factors (TNF-α and IL-1β) and TLR4/NF-κB signaling pathway than the control group. In conclusion, this study demonstrates for the beclin1 exerts both autophagic and non-autophagic functions during the inflammatory process in YEECs, making it become a potential target for the cure and diagnosis of various yak endometritis.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"147 ","pages":"Article 113940"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576924024627","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Beclin1 is an autophagy related factor, and it is capable of mediating non-autophagy functions, too. Yak endometritis represents a significant obstetric ailment that impedes the normal breeding process. The current understanding of the beclin1 effect on endometrial inflammation in yak remains limited. Accordingly, this study initially examined the expression profile of beclin1 in yak endometritis in vitro and vivo. Subsequently, the beclin1 was targeted inhibit through small interfering RNA (siRNA), with the objective of elucidating the regulatory function of beclin1 in yak endometritis. The findings reveal that expression of beclin1 in inflammatory tissues of yak endometrium is markedly elevate in comparison to control group, and predominant localization in the cytoplasm of the endometrium and uterine glands. 1 µg/mL Lipopolysaccharide (LPS) was demonstrated to induce yak endometrial epithelial cells (YEECs) inflammation and increase the expression of beclin1. YEECs are disposed with 1 μg/mL LPS, resulting in a gradual increase of p62 expression from 0 h to 6 h, and significant decrease at 12 h, at 9 h to 12 h the expression of LC3 significant increase. These findings indicate that LPS impairs autophagy during the initial stages of inflammation, complete autophagy is occurred in cells during the subsequent phase. Initial stages of inflammation, inhibit beclin1 result significantly reduced expression of inflammatory factors (TNF-α and IL-1β) and TLR4/NF-κB signaling pathway (p65, IκBα phosphorylation, p65 nuclear translocation) compared to the control group. When complete autophagy occurred, inhibit beclin1 inhibit autophagy, result in a significantly higher expression of inflammatory factors (TNF-α and IL-1β) and TLR4/NF-κB signaling pathway than the control group. In conclusion, this study demonstrates for the beclin1 exerts both autophagic and non-autophagic functions during the inflammatory process in YEECs, making it become a potential target for the cure and diagnosis of various yak endometritis.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.